Bayer stock trades steadily as Q1 2026 earnings and outlook frame investor expectations

Bayer AG (ISIN DE000BAY0017) stock is currently quoted at €49.40 on its German listing, with this level tied to a close on August 6, 2026 per market data for the BAYN.DE ticker. An earnings and guidance backdrop centered on Q1 2026 results and full-year forecasts is now a key reference point for investors evaluating the group’s recovery trajectory.

Q1 2026 revenue and earnings set the tone

Per BAYN.DE analyst data for Q1 fiscal 2026, Bayer is projected to generate revenue of €13.4 billion for the current quarter, a figure that reflects expectations for the company’s diversified pharmaceuticals, consumer health, and crop science portfolio in the period ending in early 2026. In the same Q1 2026 context, current earnings expectations stand at €2.76 billion, highlighting a substantial profitability base that helps frame discussions of leverage, cash generation, and dividend capacity.

Consensus tables for BAYN.DE further show that the current year revenue estimate is €45.72 billion, compared with a next-year estimate of €46.94 billion, signaling anticipated top-line expansion of €1.22 billion year over year based on existing forecasts. On the earnings side, the current year EPS estimate is 4.46, while the next year figure is 4.73, indicating an expected increase of 0.27 in earnings per share as the market models incremental operational improvement across Bayer’s segments.

Growth expectations and performance metrics

Forecast change data attached to the BAYN.DE symbol indicate that the current quarter is expected to show a decline of 39.32 percent relative to the prior comparable quarter, while the next quarter carries an anticipated decline of 14.00 percent on the same basis. For the full current fiscal year, the consensus implies a decline of 9.10 percent relative to the previous year, contrasted with a projected growth rate of 5.90 percent for the next year, underscoring an expected inflection once near-term headwinds are absorbed.

This quantified pattern of a currently weaker year followed by a return to mid single-digit growth gives investors a concrete framework for comparing Bayer with other large-cap European healthcare and life science names. The combination of a current year decline of 9.10 percent and a next year positive change of 5.90 percent shows how the market embeds both ongoing restructuring and legal risk management costs and a subsequent normalization phase into its valuation models.

Valuation snapshot and shareholder return context

At a share price of €48.74 reported in recent valuation commentary, Bayer has delivered a 24.24 percent 90-day share price return and a 74.01 percent total shareholder return over the past year, figures that underscore a pronounced recovery from earlier lows. In that same valuation context, a fair value estimate of €54.92 has been cited, which stands €6.18 above the latest close of €48.74 and represents a potential upside of 12.68 percent if the fair value assumption proves accurate and is ultimately reflected in the trading price.

The comparison between the current share price of €48.74 and the referenced fair value of €54.92 shows that, on this metric, Bayer trades below an indicated intrinsic value mark. For investors, the 24.24 percent 90-day return and the substantially higher 74.01 percent total shareholder return across the past year highlight that a significant part of the catch-up move has already occurred, while the fair value gap points to a residual valuation argument that still depends on execution against earnings and cash flow targets.

Representative product focus: pharmaceuticals and crop science

Bayer AG’s business is anchored in a combination of prescription pharmaceuticals, consumer health products, and crop science solutions, with the latter including seeds, traits, and crop protection offerings designed to support agricultural productivity. Within the pharmaceutical segment, the company markets therapies in cardiovascular, oncology, and women’s health areas among others, while its crop science division provides integrated solutions to farmers seeking yield stability in the face of climate variability and pest pressure.

This mix of healthcare and agricultural exposure means that Bayer’s earnings profile captures dynamics from both regulated medicine markets and global commodity-linked farming cycles. For equity investors, the presence of a large crop science arm adds cyclicality and sensitivity to planting decisions and crop pricing, while the pharmaceutical portfolio contributes recurring revenue streams that are shaped by patent cycles, reimbursement frameworks, and competitive innovation in key therapeutic areas.

Current stock level and trading venue

Bayer stock trades on the Xetra electronic market in Frankfurt under the BAYN ticker, with its €49.40 price level referenced as of the August 6, 2026 close for BAYN.DE. This German listing in euros anchors the primary liquidity pool for the shares and serves as the main reference quote for international investors tracking the company’s performance.

Company

Company: Bayer AG

ISIN: DE000BAY0017

Ticker: BAYN

Exchange: Xetra (Frankfurt)

Sector / Industry: Pharmaceuticals, crop science, and consumer health